Mineralys Therapeutics, Inc. has reported a change in ownership through a Form 3 filing, which indicates that Kristine Peterson, a director of the company, has made an ownership change. This filing is significant as it underscores the importance of transparency in corporate governance, particularly in the pharmaceutical preparations industry.
Mineralys Therapeutics, Inc. operates in the pharmaceutical preparations sector, as classified under the SIC code 2834. The company is publicly traded on the Nasdaq under the ticker symbol MLYS. As an emerging growth company, Mineralys focuses on developing innovative therapies for various medical conditions.
The filing states that the change in ownership is effective as of October 20, 2026. Kristine Peterson is noted as a director but not an officer or a ten percent owner. The document emphasizes the necessity for directors to report any changes in ownership to maintain compliance with SEC regulations.
This update may affect stakeholders, including investors and analysts who monitor corporate governance practices within the pharmaceutical sector. Transparency in ownership changes can influence investor confidence and market perceptions, highlighting the importance of such filings.
Details were not available in the SEC filing regarding any future actions or implications stemming from this ownership change.
Ownership Details
According to the SEC filing, Kristine Peterson currently owns one share of Mineralys Therapeutics, Inc. This ownership is reported under the SEC Act of 1934, which mandates that directors disclose their holdings and changes in ownership to ensure transparency and compliance with regulatory standards.
Company Background
Mineralys Therapeutics, Inc. is classified under the SIC code 2834, indicating its operations in the pharmaceutical preparations sector. The company is based in Radnor, Pennsylvania, with its business address listed as 150 N. Radnor Chester Road, Suite F200. The company was assigned the Central Index Key (CIK) number 0001933414, which is used for SEC filings.
Power of Attorney
The filing includes a Power of Attorney document that designates several individuals, including Jon Congleton, Adam Levy, Jose Breton, and Jeffrey Munsie, as attorneys-in-fact for Kristine Peterson. This allows them to act on her behalf regarding SEC filings, including Forms 3, 4, and 5, as well as other necessary documentation related to her ownership and transactions in the company's securities.
Future Reporting Obligations
The Power of Attorney remains effective until Kristine Peterson is no longer required to file reports with the SEC concerning her securities holdings. This emphasizes the ongoing commitment to compliance with SEC regulations and the importance of timely reporting in maintaining investor trust.
Details regarding any specific plans for the company or future implications of this ownership change were not mentioned in the SEC filing.